Trial · NCT01634360
Adverse events152
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 152
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Muscle Rigidity | Musculoskeletal and connective tissue disorders | Perampanel (Placebo During Core Study) | 3 | 48 | |
| other | Muscle Rigidity | Musculoskeletal and connective tissue disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 0 | 134 | |
| serious | Dyskinesia | Nervous system disorders | Perampanel (Placebo During Core Study) | 0 | 48 | |
| serious | Dyskinesia | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 3 | 134 | |
| serious | On and off phenomenon | Nervous system disorders | Perampanel (Placebo During Core Study) | 1 | 48 | |
| serious | On and off phenomenon | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 2 | 134 | |
| serious | Dementia | Nervous system disorders | Perampanel (Placebo During Core Study) | 0 | 48 | |
| serious | Dementia | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 2 | 134 | |
| serious | Balance disorder | Nervous system disorders | Perampanel (Placebo During Core Study) | 0 | 48 | |
| serious | Balance disorder | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 1 | 134 | |
| serious | Cerebrovascular accident | Nervous system disorders | Perampanel (Placebo During Core Study) | 0 | 48 | |
| serious | Cerebrovascular accident | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 1 | 134 | |
| serious | Dystonia | Nervous system disorders | Perampanel (Placebo During Core Study) | 1 | 48 | |
| serious | Dystonia | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 0 | 134 | |
| serious | Freezing phenomenon | Nervous system disorders | Perampanel (Placebo During Core Study) | 0 | 48 | |
| serious | Freezing phenomenon | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 1 | 134 | |
| serious | Hyperkinesia | Nervous system disorders | Perampanel (Placebo During Core Study) | 0 | 48 | |
| serious | Hyperkinesia | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 1 | 134 | |
| serious | Paraparesis | Nervous system disorders | Perampanel (Placebo During Core Study) | 1 | 48 | |
| serious | Paraparesis | Nervous system disorders | Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study) | 0 | 134 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01634360/events